科研之友
微信
新浪微博
Facebook
分享链接
摘要
The status of the 66-kDa human estrogen receptor-alpha (hER-alpha 66) is a critical determinant in the assessment of the prognosis and in the design of treatment strategies of human breast cancer. Recently, we cloned the cDNA of an alternatively spliced variant of hER-a66, termed hER-alpha 36; the predicted protein lacks both transcriptional activation domains of hER-a66 but retains its DNA-binding domain, partial dimerization, and ligand-binding domains and three potential myristoylation sites located near the N terminus. These findings thus predict that hER-alpha 36 functions very differently from hER-a66 in response to estrogen signaling. We now demonstrate that hER-a36 inhibits the estrogen-dependent and estrogen-independent transactivation activities of hER-a66 and hER-ss. We further demonstrate that hER-alpha 36 is predominantly associated with the plasma membrane where it transduces both estrogen- and antiestrogen-dependent activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway and stimulates cell growth. We conclude that hER-a36 is a predominantly membrane-based, unique alternatively spliced variant of hER-a66 that acts as a dominant-negative effector of both estrogen-dependent and estrogen-independent transactivation functions signaled through hER-alpha 66 and ER-ss; it also transduces membrane-initiated estrogen-dependent activation of the mitogenactivated protein kinase/extracellular signal-regulated kinase mitogenic signaling pathway. The estrogen and antiestrogen signaling pathways mediated by hER-alpha 36 provide an alternative explanation for why some human breast cancers are resistant to and others are worsened by antiestrogen therapy; the data suggest that hER-a36 also may be an important marker to direct therapy in human breast cancers, and perhaps hER-a36 also may transduce estrogen-dependent signaling in other estrogen target tissues.
- 出版日期2006-6-13
- 单位浙江大学
